Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.67. The key difference: ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | KOLD | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $49.39 |
52-Week Low | $205.48 | $13.58 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
KOLD trades at $28.54, down 0.35% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF tracks natural gas price movements inversely, with recent news highlighting volatility in natural gas markets driven by weather patterns and LNG demand. Support levels cluster around $28 with resistance at $29-$30.
As a leveraged ETF, KOLD carries significant volatility risks and is designed for short-term trading rather than long-term investment. The natural gas market faces headwinds from production levels and storage data, while geopolitical developments and weather patterns create trading opportunities for tactical investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
